MarketPulse

commercialization rights

2 articles
BenzingaBenzinga··Vandana Singh

Gilead Bolsters Inflammation Arsenal With $1.675B Ouro Medicines Deal

Gilead acquires Ouro Medicines for $1.675B upfront, targeting inflammation pipeline expansion. Galapagos NV partners to co-develop lead asset OM336.
GILDACLXGLPGacquisitionorphan drug designation
BenzingaBenzinga··Globe Newswire

Eton Pharmaceuticals Bolsters Rare Disease Portfolio With HEMANGEOL Acquisition

Eton Pharmaceuticals acquires HEMANGEOL commercialization rights, the only FDA-approved infantile hemangioma treatment, expanding its portfolio to ten commercial products with 2026 earnings accretion expected.
ETONrare diseaseorphan drug